



FOR IMMEDIATE RELEASE

PPD Achieves Recognition for Clinical Research Excellence

Wins Clinical Team of the Year in international industry competition

WILMINGTON, N.C., (May 18, 2016) – Pharmaceutical Product Development, LLC (PPD) today announced that PPD researchers earned the *PharmaTimes* International Clinical Team of the Year honor in the 2016 competition.

The award, presented at the International Clinical Researcher of the Year Awards in London on May 12, was a culmination of a demanding series of challenges, including presentations before a panel of experienced industry judges.

The industry recognition demonstrates the high caliber of PPD's [clinical research associates](#) and clinical team managers, and PPD's award-winning training and development programs, such as the Virtual Clinical Foundations Program 2.0, which help to prepare research professionals for successful [clinical trial monitoring](#) and to deliver performance, quality and value to clients and their studies.

"PPD's clinical researchers embody the utmost professionalism and competence to achieve this industry recognition," said Roger Newbery, senior vice president of clinical management for Europe, the Middle East and Africa for PPD. "We congratulate them on this achievement and recognize the talent, success and dedication our clinical researchers bring to all of our clients and their research programs."

The PPD researchers were selected as the top performing team from among finalists in a rigorous, three-stage competition. The event was created in 1999 to provide clinical research professionals an opportunity to benchmark their professional skills against their peers in a program of competency-based exercises developed through cross-industry collaboration.

About PPD

PPD is a leading global [contract research organization](#) providing comprehensive, integrated [drug development](#), [laboratory](#) and lifecycle management services. Our clients and partners include [pharmaceutical](#), [biotechnology](#), [medical device](#), academic and [government](#) organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppd.com.

PPD Contacts

Media:

Elizabeth Humphrey

+1 910 558 6096

elizabeth.humphrey@ppdi.com

Investors:

Nate Speicher

+1 910 558 6783

nate.speicher@ppdi.com

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD's award-winning clinical researchers contained in this news release, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; competition in the outsourcing industry; PPD's ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.

###